Amundi Increases Holdings in Zoetis Inc. $ZTS

Key Points

• Amundi increased its Zoetis stake by 26% in the second quarter, acquiring 822,257 additional shares and bringing its holdings to 3.99 million shares worth approximately $286.6 million.
• Zoetis reported quarterly adjusted earnings of $1.87 per share, narrowly exceeding estimates, while revenue of $2.47 billion fell slightly short of forecasts and declined 0.2% year over year.
• Shares opened at $75.70, near the lower end of their 52-week range. Analysts maintain a consensus “Hold” rating with an average price target of $107.43, despite mixed recommendations.

Amundi increased its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 26.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,988,618 shares of the company's stock after acquiring an additional 822,257 shares during the period. Amundi owned approximately 0.97% of Zoetis worth $286,622,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ZTS. RFG Advisory LLC lifted its stake in Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company's stock valued at $215,000 after purchasing an additional 80 shares during the last quarter. Financial Engines Advisors L.L.C. increased its position in Zoetis by 4.4% in the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company's stock worth $299,000 after buying an additional 87 shares during the last quarter. Physician Wealth Advisors Inc. increased its position in Zoetis by 17.4% in the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company's stock worth $73,000 after buying an additional 91 shares during the last quarter. Howland Capital Management LLC raised its stake in shares of Zoetis by 4.5% in the second quarter. Howland Capital Management LLC now owns 2,137 shares of the company's stock valued at $333,000 after buying an additional 92 shares during the period. Finally, Smithfield Trust Co raised its stake in shares of Zoetis by 4.2% in the fourth quarter. Smithfield Trust Co now owns 2,294 shares of the company's stock valued at $290,000 after buying an additional 92 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.1%

Shares of ZTS opened at $75.70 on Tuesday. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $155.15. The stock has a market cap of $31.28 billion, a PE ratio of 12.47, a P/E/G ratio of 1.77 and a beta of 0.73. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The business's 50-day moving average price is $75.58 and its 200-day moving average price is $93.26.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts' consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same period last year, the business earned $1.76 earnings per share. Zoetis's revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ZTS has been the subject of several research reports. Morgan Stanley set a $85.00 price target on Zoetis in a research note on Friday, August 7th. Zacks Research cut Zoetis from a "hold" rating to a "strong sell" rating in a research note on Monday, August 10th. HSBC dropped their price objective on shares of Zoetis from $140.00 to $95.00 and set a "buy" rating on the stock in a report on Monday, July 6th. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a research note on Tuesday, August 25th. Finally, UBS Group reduced their target price on shares of Zoetis from $85.00 to $80.00 and set a "neutral" rating for the company in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $107.43.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.